Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

Blood - Tập 111 Số 8 - Trang 3931-3940 - 2008
Ralph Tiedt1, Hui Hao-Shen1, Marta Sobas1,2, Renate Looser1, Stephan Dirnhofer3, Jürg Schwaller4, Radek C. Skoda1
1Department of Research, Experimental Hematology, University Hospital Basel, Basel, Switzerland
2Servicio de Hematologia y Hemoterapia, Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
3Institute of Pathology, University Hospital Basel, Basel, Switzerland; and
4Department of Research, Childhood Leukemia, University Hospital Basel, Basel, Switzerland

Tóm tắt

Abstract An acquired somatic mutation in the JAK2 gene (JAK2-V617F) is present in the majority of patients with myeloproliferative disorders (MPDs). Several phenotypic manifestations (polycythemia vera [PV], essential thrombocythemia [ET], and primary myelofibrosis) can be associated with the same mutation. We generated JAK2-V617F transgenic mice using a human JAK2 gene with the sequences encoding the kinase domain placed in the inverse orientation and flanked by antiparallel loxP sites. Crossing mice of one transgenic line (FF1) with transgenic mice expressing Cre-recombinase under the control of the hematopoiesis specific Vav promoter led to expression of JAK2-V617F that was lower than the endogenous wild-type Jak2. These mice developed a phenotype resembling ET with strongly elevated platelet counts and moderate neutrophilia. Induction of the JAK2-V617F transgene with the interferon-inducible MxCre resulted in expression of JAK2-V617F approximately equal to wild-type Jak2 and a PV-like phenotype with increased hemoglobin, thrombocytosis, and neutrophilia. Higher levels of JAK2-V617F in mouse bone marrow by retroviral transduction caused a PV-like phenotype without thrombocytosis. These data are consistent with the hypothesis that the ratio of mutant to wild-type JAK2 is critical for the phenotypic manifestation. A similar correlation was also found in patients with MPD.

Từ khóa


Tài liệu tham khảo

James, 2005, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera., Nature, 434, 1144, 10.1038/nature03546

Baxter, 2005, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders., Lancet, 365, 1054, 10.1016/S0140-6736(05)71142-9

Levine, 2005, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis., Cancer Cell, 7, 387, 10.1016/j.ccr.2005.03.023

Kralovics, 2005, A gain-of-function mutation of JAK2 in myeloproliferative disorders., N Engl J Med, 352, 1779, 10.1056/NEJMoa051113

Cazzola, 2005, Gain of function, loss of control–a molecular basis for chronic myeloproliferative disorders., Haematologica, 90, 871

Kralovics, 2002, Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera., Exp Hematol, 30, 229, 10.1016/S0301-472X(01)00789-5

Lacout, 2006, JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis., Blood, 108, 1652, 10.1182/blood-2006-02-002030

Wernig, 2006, Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model., Blood, 107, 4274, 10.1182/blood-2005-12-4824

Bumm, 2006, Characterization of murine JAK2V617F-positive myeloproliferative disease., Cancer Res, 66, 11156, 10.1158/0008-5472.CAN-06-2210

Zaleskas, 2006, Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F., PLoS ONE, 1, 18, 10.1371/journal.pone.0000018

Zaleskas, 2005, Molecular pathogenesis of polycythemia induced in mice by JAK2 V617F., Blood, 106

Luoh, 2000, Role of the distal half of the c-Mpl intracellular domain in control of platelet production by thrombopoietin in vivo., Mol Cell Biol, 20, 507, 10.1128/MCB.20.2.507-515.2000

Lee, 2001, A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA., Genomics, 73, 56, 10.1006/geno.2000.6451

Zhang, 2002, Cre recombinase-mediated inversion using lox66 and lox71: method to introduce conditional point mutations into the CREB-binding protein., Nucleic Acids Res, 30, 90, 10.1093/nar/gnf089

Schwaller, 1998, Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes., Embo J, 17, 5321, 10.1093/emboj/17.18.5321

Beillard, 2003, Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using “real-time” quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)–a Europe against cancer program., Leukemia, 17, 2474, 10.1038/sj.leu.2403136

Lippert, 2006, The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera., Blood, 108, 1865, 10.1182/blood-2006-01-013540

Kralovics, 2006, Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders., Blood, 108, 1377, 10.1182/blood-2005-11-009605

Kralovics, 2003, Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders., Blood, 102, 1869, 10.1182/blood-2003-03-0744

de Boer, 2003, Transgenic mice with hematopoietic and lymphoid specific expression of Cre., Eur J Immunol, 33, 314, 10.1002/immu.200310005

Kuhn, 1995, Inducible gene targeting in mice., Science, 269, 1427, 10.1126/science.7660125

Leveen, 2005, TGF-beta type II receptor-deficient thymocytes develop normally but demonstrate increased CD8+ proliferation in vivo., Blood, 106, 4234, 10.1182/blood-2005-05-1871

Birgegard, 1992, Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment., Br J Haematol, 81, 603, 10.1111/j.1365-2141.1992.tb02999.x

Mossuz, 2004, Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis., Haematologica, 89, 1194

Vannucchi, 2007, Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia., Blood, 110, 840, 10.1182/blood-2006-12-064287

Dupont, 2007, The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera., Blood, 110, 1013, 10.1182/blood-2006-10-054940

Royer, 2005, Janus kinases affect thrombopoietin receptor cell surface localization and stability., J Biol Chem, 280, 27251, 10.1074/jbc.M501376200

Horikawa, 1997, Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia., Blood, 90, 4031, 10.1182/blood.V90.10.4031

Moliterno, 1998, Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera., N Engl J Med, 338, 572, 10.1056/NEJM199802263380903

Moliterno, 1999, Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera., Blood, 94, 2555, 10.1182/blood.V94.8.2555.420k14_2555_2561

Moliterno, 2006, Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression., Blood, 108, 3913, 10.1182/blood-2006-03-008805

Giraldo, 2001, Size matters: use of YACs, BACs and PACs in transgenic animals., Transgenic Res, 10, 83, 10.1023/A:1008918913249

Casanova, 2001, A CamKIIalpha iCre BAC allows brain-specific gene inactivation., Genesis, 31, 37, 10.1002/gene.1078

Zhang, 2004, Highly restricted expression of Cre recombinase in cerebellar Purkinje cells., Genesis, 40, 45, 10.1002/gene.20062

Ogilvy, 1999, Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment., Blood, 94, 1855, 10.1182/blood.V94.6.1855

Almarza, 2004, Regulatory elements of the vav gene drive transgene expression in hematopoietic stem cells from adult mice., Exp Hematol, 32, 360, 10.1016/j.exphem.2004.01.005

Passamonti, 2006, Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders., Blood, 107, 3676, 10.1182/blood-2005-09-3826

Scott, 2006, Progenitors homozygous for the V617F JAK2 mutation occur in most patients with polycythemia vera, but not essential thrombocythemia., Blood, 108, 2435, 10.1182/blood-2006-04-018259

Scott, 2007, JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis., N Engl J Med, 356, 459, 10.1056/NEJMoa065202

Pietra, 2008, Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders., Blood, 111, 1686, 10.1182/blood-2007-07-101576

Thông tin
Thông tin xuất bản

Blood

Tập 111 Số 8

3931-3940

Thông tin tác giả